226 related articles for article (PubMed ID: 27287872)
1. Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer.
Chida S; Okayama H; Noda M; Saito K; Nakajima T; Aoto K; Hayase S; Momma T; Ohki S; Kono K; Takenoshita S
Carcinogenesis; 2016 Sep; 37(9):878-887. PubMed ID: 27287872
[TBL] [Abstract][Full Text] [Related]
2. KRT17 as a prognostic biomarker for stage II colorectal cancer.
Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
[TBL] [Abstract][Full Text] [Related]
3. LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival.
Torres S; Garcia-Palmero I; Herrera M; Bartolomé RA; Peña C; Fernandez-Aceñero MJ; Padilla G; Peláez-García A; Lopez-Lucendo M; Rodriguez-Merlo R; García de Herreros A; Bonilla F; Casal JI
Clin Cancer Res; 2015 Nov; 21(21):4892-902. PubMed ID: 26206869
[TBL] [Abstract][Full Text] [Related]
4. Lumican and versican are associated with good outcome in stage II and III colon cancer.
de Wit M; Belt EJ; Delis-van Diemen PM; Carvalho B; Coupé VM; Stockmann HB; Bril H; Beliën JA; Fijneman RJ; Meijer GA
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S348-59. PubMed ID: 22711178
[TBL] [Abstract][Full Text] [Related]
5. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle proteins predict recurrence in stage II and III colon cancer.
Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
8. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients.
Dekervel J; Hompes D; van Malenstein H; Popovic D; Sagaert X; De Moor B; Van Cutsem E; D'Hoore A; Verslype C; van Pelt J
Clin Cancer Res; 2014 Apr; 20(8):2159-68. PubMed ID: 24486594
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of stromal GREM1 expression in colorectal cancer.
Jang BG; Kim HS; Chang WY; Bae JM; Oh HJ; Wen X; Jeong S; Cho NY; Kim WH; Kang GH
Hum Pathol; 2017 Apr; 62():56-65. PubMed ID: 28041973
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer.
Hazelbag S; Kenter GG; Gorter A; Fleuren GJ
Int J Cancer; 2004 Dec; 112(6):1020-8. PubMed ID: 15386352
[TBL] [Abstract][Full Text] [Related]
13. Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.
den Uil SH; Coupé VM; Linnekamp JF; van den Broek E; Goos JA; Delis-van Diemen PM; Belt EJ; van Grieken NC; Scott PM; Vermeulen L; Medema JP; Bril H; Stockmann HB; Cormier RT; Meijer GA; Fijneman RJ
Br J Cancer; 2016 Dec; 115(12):1565-1574. PubMed ID: 27855440
[TBL] [Abstract][Full Text] [Related]
14. Desmoplastic Pattern at the Tumor Front Defines Poor-prognosis Subtypes of Colorectal Cancer.
Ueno H; Kanemitsu Y; Sekine S; Ishiguro M; Ito E; Hashiguchi Y; Kondo F; Shimazaki H; Mochizuki S; Kajiwara Y; Shinto E; Yamamoto J
Am J Surg Pathol; 2017 Nov; 41(11):1506-1512. PubMed ID: 28877064
[TBL] [Abstract][Full Text] [Related]
15. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer.
Park JS; Chon HJ; Jeung HC; Shin SJ; Rha SY; Ahn JB; Lee KY; Kim NK; Chung HC
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2051-9. PubMed ID: 27447697
[TBL] [Abstract][Full Text] [Related]
16. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.
Belt EJ; Fijneman RJ; van den Berg EG; Bril H; Delis-van Diemen PM; Tijssen M; van Essen HF; de Lange-de Klerk ES; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Eur J Cancer; 2011 Aug; 47(12):1837-45. PubMed ID: 21621406
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.
Ghosh S; Albitar L; LeBaron R; Welch WR; Samimi G; Birrer MJ; Berkowitz RS; Mok SC
Gynecol Oncol; 2010 Oct; 119(1):114-20. PubMed ID: 20619446
[TBL] [Abstract][Full Text] [Related]
18. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Sluiter NR; de Cuba EM; Kwakman R; Meijerink WJ; Delis-van Diemen PM; Coupé VM; Beliën JA; Meijer GA; de Hingh IH; te Velde EA
Clin Exp Metastasis; 2016 Apr; 33(4):297-307. PubMed ID: 26873137
[TBL] [Abstract][Full Text] [Related]
19. Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival.
Zhao Z; Han FH; Yang SB; Hua LX; Wu JH; Zhan WH
World J Gastroenterol; 2015 Jan; 21(4):1140-7. PubMed ID: 25632186
[TBL] [Abstract][Full Text] [Related]
20. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
